Many ICON PLC(ICLR) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. ICON PLC was Upgraded by Goldman to Buy on Dec 16, 2016. ICON PLC was Downgraded by SunTrust to Hold on Dec 16, 2016.
ICON PLC Last issued its quarterly earnings results on Oct 20, 2016. The company reported $1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $1.18. The company had revenue of $420.20 million for the quarter, compared to analysts expectations of $419.53 million. The companys revenue was up 6.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.02 EPS.
ICON plc (NASDAQ:ICLR) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.17 by 12 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 7 Brokerage Firms have advised hold.
ICON plc (NASDAQ:ICLR): The stock price is expected to reach $ 82.13 in the short term. The number of analysts agreeing with this consensus is 8. The higher estimate for the short term price target is at $93 while the lower estimate is at $59. The standard deviation of the price stands at $11.59.
ICON plc (NASDAQ:ICLR) rose 2.02% or 1.71 points on Tuesday and made its way into the gainers of the day. After trading began at $84.73 the stock was seen hitting $87.27 as a peak level and $84.545 as the lowest level. The stock ended up at $86.42. The daily volume was measured at 624,614 shares. The 52-week high of the share price is $87.27 and the 52-week low is $62.31. The company has a market cap of $4,787 million.
ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.